TE_133
Basic information Differential Expression Stage analysis Survival analysis Correlation analysis| TE family | THE1A |
|---|---|
| TE superfamily | MaLR |
| TE class | LTR |
| Gene | - |
| Class | Intergenic |
| Coding | Non-coding |
| Tumor-specific score | 3.12 |
| Counts of samples | TCGA_tumor:1706; TCGA_normal:49; GTEx:567 |
| TSS | chr1(-):15323064 |
Transcript isoforms
| Transcript_ID | Gene | Class | Coding | ORF | Position |
|---|---|---|---|---|---|
| teRNA_133.11 | - | Intergenic | Non-coding | Non-coding | chr1(-):15289729,15289749,15317259,15317413,15322908,15323065 |
| teRNA_133.12 | - | Intergenic | Non-coding | Non-coding | chr1(-):15313048,15313068,15317259,15317413,15322908,15323065 |
| teRNA_133.13 | - | Intergenic | Non-coding | Non-coding | chr1(-):15317163,15317183,15317317,15317413,15322908,15323065 |
| teRNA_133.14 | - | Intergenic | Non-coding | Non-coding | chr1(-):15312634,15312654,15312867,15313068,15317259,15317413,15322908,15323065 |
| teRNA_133.15 | - | Intergenic | Non-coding | Non-coding | chr1(-):15316596,15316616,15317259,15317413,15322908,15323065 |
| teRNA_133.16 | - | Intergenic | Non-coding | Non-coding | chr1(-):15312050,15312070,15312537,15312654,15322908,15323065 |
| teRNA_133.17 | - | Intergenic | Non-coding | Non-coding | chr1(-):15289729,15289749,15291801,15291933,15322908,15323065 |
| teRNA_133.18 | - | Intergenic | Non-coding | Non-coding | chr1(-):15289729,15289749,15291651,15291933,15322908,15323065 |
| teRNA_133.19 | - | Intergenic | Non-coding | Non-coding | chr1(-):15289729,15289749,15311837,15312070,15322908,15323065 |
| teRNA_133.20 | - | Intergenic | Non-coding | Non-coding | chr1(-):15312050,15312070,15312867,15313068,15322908,15323065 |
GTEx
The proportion of samples in which the TE-initiated transcript was expressed across 46 body sites in the Genotype-Tissue Expression (GTEx) project.
TCGA
The proportion of samples in which the TE-initiated transcript was expressed across 33 cancer types from The Cancer Genome Atlas (TCGA).
GTEx
The expression of TE-initiated transcript across 46 body sites from The Genotype-Tissue Expression (GTEx) project.
